Momentum Biotechnologies Launches Proteomics as New Service Offering

BILLERICA, Mass., Nov. 29, 2023 /PRNewswire/ -- Momentum Biotechnologies, a leading provider of mass spectrometry-based analytical drug discovery services, has announced the launch of new services focused on proteomics. Offerings will include targeted and global proteomics, chemoproteomics and comparative proteomics using TMT-labelling protocols. Momentum has made significant investments in hardware, automation and a world-class team of scientific experts. 

For almost a decade, Momentum has been offering clients a wide range of early drug discovery services including high-throughput screening, hit characterization and hit-to-lead development. Momentum uses mass spectrometry-based approaches for label-free functional assays as well as covalent and non-covalent binding assays against protein and RNA targets. "With the addition of our proteomics capabilities, we will be able to continue interrogating chemistry identified from in vitro experiments in cellular and downstream assays," said Can Ozbal, Ph.D. CEO of Momentum. "Proteomics is the latest milestone in our quest to streamline the ability of our clients to develop the next generation of pharmaceuticals."

One example of the extension of services enabled by proteomics is in irreversible covalent binding studies. Momentum has been offering a high-throughput intact mass shift assay to identify electrophilic test compounds that bind protein targets for several years. "We can now help our clients characterize the binding site of the covalent adduct by doing peptide mapping," said Peter Rye, Ph.D., Vice President of Application Development and head of the proteomics team. "We can further characterize those test compounds in cellular assays showing on and off target binding in vivo".

Momentum's new proteomics service offerings go beyond chemo-proteomics and covalently modified targets and include protein identification, sequencing, expression differences between groups, and interaction with other proteins. "Our customers are excited about these new capabilities and are looking forward to additional offerings we're planning for next year," Ozbal said. 

About Momentum Biotechnologies

Momentum Biotechnologies is a drug discovery partner that delivers innovative mass spec solutions to overcome research challenges for biopharma clients globally. Our core team of scientists and engineers started working together developing the RapidFire high-throughput MS platform and have been serving clients with MS-based services since 2004.

Momentum Biotechnologies' goal is to accelerate our partners' drug discovery & development programs through superior mass spec-based CRO services. We help clients identify and characterize leads for degraders, molecular glues, protein-protein interaction (PPI) disrupters, RNA binders and other target classes. We use innovative techniques including affinity selection MS (ASMS), intact mass MS, chemoproteomics and small & biomolecule analyses. We pride ourselves on rapid turnaround of the highest quality data, accelerating the momentum of our clients' research projects. For more information, please visit www.momentum.bio.

SOURCE Momentum Biotechnologies